RespirAI Medical

RespirAI Medical Overview

RespirAI Medical is developing a wearable disease-management platform for home monitoring. The companys technology enables patients to manage multiple health conditions, improving their quality of life and reducing costs to the healthcare system. The system enables changes in patient health to be detected at an early stage, before the patient reports symptoms or experiences physiological decline. RespirAIs easy-to-wear passive sensing technology captures medical-grade physiological data a few minutes a day for long-term patient monitoring. Deviations from the patients clinical baselines are automatically synced to the cloud for analysis using advanced algorithms and artificial intelligence capabilities, and the results are shared with the patients care team and family. The systems core technology is based on an invention of researchers from the University of Nebraska at Omaha.

Cumulative Funding Raised Over Time ($)

Latest News

Aug 4, 2024 · www.israel21c.org

growth-positive

COPD flareups could be predicted via smartwatch  - ISRAEL21c

RespirAI, a Tel Aviv-based company, has developed an AI algorithm to predict COPD flareups using data from wearable devices. This innovation aims to address the unmet need for monitoring pulmonary issues like COPD, which affects millions worldwide. The company is conducting clinical trials in Israel and plans to launch its product by 2026. RespirAI has raised $2 million, primarily from eHealth Ventures, and has partnered with the Mayo Clinic to develop a platform for monitoring COPD. Despite challenges posed by the conflict in Gaza, RespirAI continues to advance its technology, aiming to improve patient outcomes and reduce healthcare costs.

InvestmentPartners

Apr 8, 2024 · www.calcalistech.com

growth-positive

RespirAI prepares to set the “smoker’s disease” alight with new digital health platform | CTech

RespirAI, a digital health company, has raised a total of $1.1 million to develop an AI-based platform for real-time monitoring of respiratory conditions, particularly COPD. The company aims to address the unmet need for accurate disease status assessment and prediction of exacerbations in chronic pulmonary diseases. The funds will be used for advancing clinical trials, regulatory approvals, and market preparation. RespirAIs platform uses FDA-approved sensors and a patented AI algorithm to provide comprehensive monitoring and personalized insights, empowering patients and healthcare providers. The product is expected to launch in 2026, targeting COPD patients and healthcare payers seeking remote monitoring solutions.

Investment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Smadar St 7, Herzliya, Israel

Photos & Videos

No files yet

RespirAI Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info